The largest database of trusted experimental protocols

6460 series triple quadrupole lc ms

Manufactured by Agilent Technologies
Sourced in United States

The 6460 Series Triple Quadrupole LC/MS is a high-performance liquid chromatography-mass spectrometry (LC/MS) system designed for accurate and sensitive quantitative analysis. It features a triple quadrupole mass analyzer that provides reliable and reproducible results.

Automatically generated - may contain errors

9 protocols using 6460 series triple quadrupole lc ms

1

Nuclear Proteome Analysis of U251 and U87 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The nuclei were obtained from U251 and U87 cells and analysed using LC–MS/MS. In brief, nuclear extracts were processed for protein precipitation followed by solid-phase extraction. Fifteen per cent trichloroacetic acid (TCA) in water was applied to remove proteins and other interference substances from the nuclear samples. The supernatant was subsequently transferred to a Waters HLB solid-phase extraction cartridge for further sample clean-up. The final reconstitution samples were injected into a Gemini C6-phenyl 100 × 4.6 mm 3 μM high-performance liquid chromatography column (Phenomenex). The mobile phase consisted of ammonium acetate and acetic acid in both aqueous and organic phases. Data acquisition was performed using a 6460 Series Triple Quadrupole LC/MS (Agilent Technologies) via multiple reaction mode (MRM) electrospray positive mode.
+ Open protocol
+ Expand
2

Quantifying Plasma TMAO Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma was stored at −80°C until analysis. The TMAO levels in plasma were determined using stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent), as described previously.19Plasma (50 μL) was aliquoted to a 1.5‐mL tube and mixed with 200 μL of a 10 μmol/L internal standard composed of d9‐TMAO in methanol. The samples were vortexed for 1 minute, and then the supernatant was recovered following centrifugation at 15 000g at 4°C for 25 minutes. The supernatant (2 μL) was injected directly into a silica column (4.6×250 mm, 5 μm Luna silica, catalog no. 00G‐4274‐E0; Phenomenex) at a flow rate of 0.5 mL/min−1 with 80% solvent A (0.1% formic acid in water) and 20% solvent B (methanol). TMAO and d9‐TMAO were monitored in the positive multiple reaction monitoring mass spectrometry mode using characteristic precursor–production transitions including m/z 76/58 and m/z 85/66, respectively. To calculate the TMAO concentration, various concentrations of a TMAO standard were added to control plasma to prepare the calibration curves.
+ Open protocol
+ Expand
3

TMAO Quantification by LC-MS/MS

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum concentrations of TMAO were quantified by stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent, CA, United States) as described previously (Wang et al., 2014 (link)).
+ Open protocol
+ Expand
4

Quantifying Plasma TMAO Levels by LC-MS/MS

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma aliquots were stored at −40 °C prior to analysis. The plasma TMAO concentrations were quantified using stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent) as previously described52 (link).
The molecular weight of TMAO is 75.22 g/mol. The extracted plasma aliquots were spiked with internal standards comprised of d9-TMAO in methanol. The samples were mechanically vortexed for 1 minute and centrifuged at 15,000 × g for 25 minutes at 4 °C. The analytes were separated on a phenomenex Luna Silica column (4.6 mm × 250 mm, 5 μm particle size) at room temperature. The mobile phase consisted of 80% solvent A (0.1% formic acid in water) and 20% solvent B (methanol) at a flow rate of 0.5 mL/min. The MS/MS analyses for TMAO and d9-TMAO were conducted in the positive multiple reaction monitoring mass spectrometry mode at m/z 76 → 58 and m/z 85 → 66, respectively. To calculate the TMAO concentration, various concentrations of a TMAO standard were added to control plasma to prepare calibration curves. The data were collected and analysed using the chemistry station provided by Agilent Technology.
+ Open protocol
+ Expand
5

Fasting Plasma Biomarkers in Metabolism

Check if the same lab product or an alternative is used in the 5 most similar protocols
Overnight fasting (≥8 h) venous blood samples were collected using vacuum tubes containing EDTA. The levels of TMAO and L-carnitine were determined using stable isotope dilution liquid chromatography–tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent, Santa Clara, CA, USA). Serum levels of fasting lipids including alanine aminotransferase (ALT), albumin (ALB), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), uric acid (UA), and creatinine obtained at baseline were measured using automatic clinical analyzers (Beckman Coulter) at the Shenzhen Tailored Medical Laboratory.
A standard questionnaire was used to collect information on the socioeconomic status, lifestyle behaviors, and medical history of participants and their family members. Body measurements were conducted for all participants by trained medical staff.
+ Open protocol
+ Expand
6

Quantifying Plasma TMAO Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
The collected blood samples were immediately processed and stored at −80°C until analysis. Plasma TMAO levels were quantified by stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent) using a d9-(trimethyl)-labeled internal standard, as previously described (23 (link)).
In total, 50 μL of plasma was added to a 1.5 mL Eppendorf tube and mixed with 200 μL of 10 μmol/L internal standard composed of d9-TMAO in methanol. The samples were vortexed for 1 min, and then the supernatant was aliquoted following centrifugation at 15,000 g and 4°C for 25 min. Two microliters of supernatant was injected directly into a silica column (4.69 × 250 mm, 5 μm Luna silica, catalog no. 00G-4274-E0; Phenomenex) at a flow rate of 0.5 mL/min−1 with 80% solvent A (0.1% formic acid in water) and 20% solvent B (methanol). TMAO and d9-TMAO were monitored in the positive multiple reaction monitoring mass spectrometry mode using characteristic precursor–production transitions including m/z 76/58 and m/z 85/66, respectively. To calculate TMAO concentrations, serial concentrations of TMAO standard were added to control plasma to prepare a calibration curve.
+ Open protocol
+ Expand
7

Serum Biomarkers in Kidney Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols
Baseline morning serum samples were collected from all patients, following an overnight fast. Serum folate and vitamin B12 were measured by a commercial laboratory with the use of a chemiluminescent immunoassay (New Industrial). Serum trimethylamine‐N‐oxide (TMAO) was quantified by stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent, CA, USA). Serum total homocysteine (tHcy), fasting lipids, and glucose concentrations were measured with automatic clinical analyzers (Beckman Coulter) at the core laboratory of the National Clinical Research Center for Kidney Disease, Nanfang Hospital, Guangzhou, China. Plasma vitamin B5 was measured by liquid chromatography–tandem mass spectrometry (LC‐MS/MS) in the central laboratory (Shenzhen). Estimated glomerular filtration rate (eGFR) was calculated using the equation according to the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI).
+ Open protocol
+ Expand
8

Effects of TMAO on 5/6 Nephrectomized Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male Sprague-Dawley rats (at the age of 5-6 weeks, initial weight 180-200 g; Southern Medical University Animal Experiment Center) were subdivided into 3 groups randomly, and 5 in each group. The first group received sham operation, while the other 2 groups received five-sixths nephrectomy (5/6 Nx) as described previously [14] . Six weeks after the operation, the two groups of 5/6 Nx rats were subjected to intraperitoneal injection with 2.5% glucose peritoneal dialysis fluid (PDF; Baxter Health Care, Deerfield, IL, USA) and 2.5% glucose PDF plus TMAO 20 mg/kg/day (Sigma-Aldrich, St. Louis, MO, USA), respectively. The sham group was injected with PBS every day. Six weeks after injection, all the rats were sacrificed, and blood samples and kidney tissues were collected. Serum TMAO was detected by stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent, Santa Clara, CA, USA).
+ Open protocol
+ Expand
9

Quantifying TMAO, Choline, and L-Carnitine

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum concentrations of TMAO, choline, and L-carnitine were quantified by stable isotope dilution liquid chromatography tandem mass spectrometry (6460 Series Triple Quadrupole LC/MS; Agilent, CA) as described previously. 9 (link) A volume of 50 μL of either the serum sample or standards were combined with 100 μL of acetonitrile containing 10 μM of internal standards (d9-choline, d9-carnitine, and d9-TMAO) and then centrifuged at 14 000 g for 15 minutes. After an additional centrifugation step, the supernatant was analyzed after injection into a normal-phase silica column (2.1×50 mm, 2.7 μm) and equilibrated with 19% solution A (10 mmol/L ammonium formate and 0.1% formate acid in water) and 81% solution B (acetonitrile) under isocratic elution with the flow rate of 0.3 mL/min.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!